Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors*

Because a subpopulation of cancer stem cells (tumor-initiating cells, TICs) is believed to be responsible for the development, progression, and recurrence of many tumors, we evaluated the in vitro sensitivity of human glioma TICs to epidermal growth factor receptor (EGFR) kinase inhibitors (erlotinib and gefitinib) and possible molecular determinants for their effects. Cells isolated from seven glioblastomas (GBM 1-7) and grown using neural stem cell permissive conditions were characterized for in vivo tumorigenicity, expression of tumor stem cell markers (CD133, nestin), and multilineage differentiation properties, confirming that these cultures are enriched in TICs. TIC cultures were challenged with increasing concentrations of erlotinib and gefitinib, and their survival was evaluated after 1-4 days. In most cases, a time- and concentration-dependent cell death was observed, although GBM 2 was completely insensitive to both drugs, and GBM 7 was responsive only to the highest concentrations tested. Using a radioligand binding assay, we show that all GBM TICs express EGFR. Erlotinib and gefitinib inhibited EGFR and ERK1/2 phosphorylation/activation in all GBMs, irrespective of the antiproliferative response observed. However, under basal conditions GBM 2 showed a high Akt phosphorylation that was completely insensitive to both drugs, whereas GBM 7 was completely insensitive to gefitinib, and Akt inactivation occurred only for the highest erlotinib concentration tested, showing a precise relationship with the antiproliferative effects of the drug. Interestingly, in GBM 2, phosphatase and tensin homolog expression was significantly down-regulated, possibly accounting for the insensitivity to the drugs. In conclusion, glioma TICs are responsive to anti-EGFR drugs, but phosphatase and tensin homolog expression and Akt inhibition seem to be necessary for such effect.

[1]  L. Muzio,et al.  Effects of Emx2 inactivation on the gene expression profile of neural precursors , 2006, The European journal of neuroscience.

[2]  Yoshimasa Uehara,et al.  Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. , 2002, Molecular cancer therapeutics.

[3]  S. Anderson,et al.  Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis , 1999, The Journal of Biological Chemistry.

[4]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[5]  M. Robello,et al.  Chemokine Stromal Cell-Derived Factor 1α Induces Proliferation and Growth Hormone Release in GH4C1 Rat Pituitary Adenoma Cell Line through Multiple Intracellular Signals , 2006, Molecular Pharmacology.

[6]  D. Durden,et al.  Mechanisms of Disease: the PI3K–Akt–PTEN signaling node—an intercept point for the control of angiogenesis in brain tumors , 2007, Nature Clinical Practice Neurology.

[7]  H. Mehdorn,et al.  Expression of stem cell markers in human astrocytomas of different WHO grades , 2007, Journal of Neuro-Oncology.

[8]  A. Bajetto,et al.  EGFR inhibitors and glioblastoma tumor initiating cells 1 DIFFERENT RESPONSE OF HUMAN GLIOMA TUMOR-INITIATING CELLS TO EGFR KINASE INHIBITORS , 2009 .

[9]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[11]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[12]  G. Stassi,et al.  Cancer stem cells – old concepts, new insights , 2008, Cell Death and Differentiation.

[13]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[14]  S. Rafii,et al.  AC133/CD133/Prominin-1. , 2005, The international journal of biochemistry & cell biology.

[15]  H. Poulsen,et al.  The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[17]  E. Parati,et al.  Epidermal and Fibroblast Growth Factors Behave as Mitogenic Regulators for a Single Multipotent Stem Cell-Like Population from the Subventricular Region of the Adult Mouse Forebrain , 1999, The Journal of Neuroscience.

[18]  Guido Reifenberger,et al.  Pten signaling in gliomas. , 2002, Neuro-oncology.

[19]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[20]  T. Palmer,et al.  Fibroblast Growth Factor-2 Activates a Latent Neurogenic Program in Neural Stem Cells from Diverse Regions of the Adult CNS , 1999, The Journal of Neuroscience.

[21]  M. Kuwano,et al.  Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.

[22]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[23]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[24]  P. Stork,et al.  G Protein Activation of a Hormone-Stimulated Phosphatase in Human Tumor Cells , 1992, Science.

[25]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[26]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[27]  J. Hainfellner,et al.  Malignant glioma: Neuropathology and Neurobiology , 2006, Wiener Medizinische Wochenschrift.

[28]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[29]  G. Lapertosa,et al.  Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative Activity , 2004, Journal of Neuro-Oncology.

[30]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[31]  Arturo Alvarez-Buylla,et al.  EGF Converts Transit-Amplifying Neurogenic Precursors in the Adult Brain into Multipotent Stem Cells , 2002, Neuron.

[32]  P. Lichter,et al.  Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients , 2008, Clinical Cancer Research.

[33]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[34]  U. Rodeck,et al.  Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. , 2003, Cancer research.

[35]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[36]  T. Florio.  Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases , 2008, Molecular and Cellular Endocrinology.

[37]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[38]  M. Diehn,et al.  Cancer stem cells and radiotherapy: new insights into tumor radioresistance. , 2006, Journal of the National Cancer Institute.

[39]  A. Dowlati,et al.  Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. , 2004, Molecular cancer therapeutics.

[40]  S. Weiss,et al.  A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[41]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[42]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[43]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[44]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Dirks,et al.  Cancer stem cells in nervous system tumors , 2004, Oncogene.

[46]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[47]  A. Ratto,et al.  17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment , 2008, Molecular Pharmacology.

[48]  M. Culler,et al.  Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. , 2008, Endocrine-related cancer.

[49]  T. Iwama,et al.  Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells* , 2008, Journal of Biological Chemistry.

[50]  W. Kamphorst,et al.  Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma? , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  A. Fusco,et al.  The Expression of the Phosphotyrosine Phosphatase DEP-1/PTPη Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation* , 2004, Journal of Biological Chemistry.

[52]  Michael F Clarke,et al.  Recent advances in cancer stem cells. , 2008, Current opinion in genetics & development.

[53]  Fang Tan,et al.  The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.